🟢 Tscan Therapeutics is trading 5% up today amid a biotech risk-on rotation

Tscan Therapeutics is trading at $0.35, up +5.05%, primarily as part of a broader biotech risk-on rotation.

• No fresh company-specific announcement or filing dated September 22, 2026 was identified; the latest major update was the September 2 strategic reorganization.
• Biotechnology ETF XBI is up 2.07%, while broader markets remain mixed.
• The move appears primarily sector-driven rather than a response to a newly reported corporate catalyst.